专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20070031392A1 Delivery vehicle for recombinant proteins 有权
标题翻译：载体重组蛋白
公开(公告)号：US20070031392A1
公开(公告)日：2007-02-08
申请号：US11581559
申请日：2006-10-16
申请人： Douglas Cines , Mortimer Poncz
发明人： Douglas Cines , Mortimer Poncz
IPC分类号： A61K48/00 , C12N5/08
CPC分类号： C12N5/0644 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0381 , A61K48/00 , A61K2035/124 , C07K14/522 , C07K14/721 , C12N15/8509 , C12N2517/02 , C12N2830/008 , C12N2830/85
摘要： Recombinant nucleic acid molecules are constructed with a first sequence encoding a transgene under the control of regulatory sequences that direct expression of the transgene product in a hematopoietic stem cell, or a progenitor cell therefrom or cell differentiated therefrom. In one embodiment, the cell which expresses the transgene is a secretory cell. The cell is a megakaryotic progenitor cell, or a cell further differentiated therefrom, such as a platelet. The cell is a granulocyte/macrophage progenitor cell or a cell further differentiated therefrom, such as a mast cell or neutrophils. Such host cells containing the molecule or the molecule itself are employed in methods for treating or preventing infection, inflammation or vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage.
摘要翻译：用编码转基因的第一序列构建重组核酸分子，所述第一序列在调节序列的控制下，所述调节序列将转基因产物在其造血干细胞或祖细胞中表达，或从其分化的细胞。在一个实施方案中，表达转基因的细胞是分泌细胞。细胞是巨核细胞祖细胞或进一步从其分化的细胞，例如血小板。细胞是粒细胞/巨噬细胞祖细胞或进一步从其分化的细胞，例如肥大细胞或嗜中性粒细胞。含有该分子或分子本身的宿主细胞本身用于治疗或预防感染，炎症或血管损伤或涉及造血谱系细胞的任何紊乱的任何障碍的方法。

82. 发明授权

US07122639B2 Chemokine alpha-2 antibodies 失效
标题翻译：趋化因子α-2抗体
公开(公告)号：US07122639B2
公开(公告)日：2006-10-17
申请号：US10267900
申请日：2002-10-10
申请人： Jian Ni , Reiner L. Gentz , Jeffrey Y. Su , Haodong Li
发明人： Jian Ni , Reiner L. Gentz , Jeffrey Y. Su , Haodong Li
IPC分类号： A16K39/395 , G01N33/567 , C07K1/00 , C12N5/12 , C12P21/20
CPC分类号： C07K14/522 , A61K38/00 , A61K48/00 , C07K2319/00 , C12N2799/026
摘要： Human chemokine Alpha-2-polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are method for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptides in a host.
摘要翻译：公开了人趋化因子α-2-多肽和编码这种趋化性细胞因子的DNA（RNA）以及通过重组技术产生此类多肽的方法。还公开了利用这种趋化性细胞因子治疗白血病，肿瘤，慢性感染，自身免疫疾病，纤维化病症，伤口愈合和牛皮癣的方法。还公开了抗这种趋化性细胞因子的拮抗剂及其作为治疗类风湿性关节炎，自身免疫性和慢性和急性炎性和感染性疾病，过敏反应，前列腺素不依赖性发烧和骨髓衰竭的治疗剂的用途。还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。还公开了用于检测编码趋化性细胞因子的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定法。

83. 发明申请

US20040057925A1 Methods of enhancing bioactivity of chemokines 审中-公开
标题翻译：增强趋化因子生物活性的方法
公开(公告)号：US20040057925A1
公开(公告)日：2004-03-25
申请号：US10146182
申请日：2002-05-15
申请人： SmithKline Beecham Corporation
发明人： Louis Martin Pelus , Pradip Kumar Bhatnagar , Andrew Garrison King , Joanna Maria Balcarek
IPC分类号： A61K038/19 , C07K014/52 , C07H021/04 , C12P021/02 , C12N005/06
CPC分类号： C07K7/06 , A61K38/00 , C07K5/0819 , C07K7/08 , C07K14/522
摘要： The present invention provides method of increasing the biological activity of KC, gro-null, gro-null, and gro-null proteins, truncated and modified proteins characterized by having biological activity at least 1 log better than the full-length protein, and pharmaceutical compositions containing same.
摘要翻译：本发明提供增加KC，gro-α，gro-β和gro-γ蛋白的生物活性的方法，其特征在于具有比全长蛋白质至少1log的生物活性的截短和修饰的蛋白质，以及药物含有它们的组合物。

84. 发明申请

US20030229203A1 Chemokine variants and methods of use 审中-公开
标题翻译：趋化因子变体和使用方法
公开(公告)号：US20030229203A1
公开(公告)日：2003-12-11
申请号：US10392355
申请日：2003-03-18
发明人： Tamas Oravecz , Michael A. Norcross
IPC分类号： C07K014/715 , C07H021/04 , C12P021/02 , C12N005/06
CPC分类号： C12N9/48 , A61K38/00 , C07K14/522 , C07K14/523
摘要： The present invention provides the nucleotide and amino acid sequence of truncated RANTES (3-68), which has the same amino acid sequence as the wild-type RANTES, but with a Serine/Proline truncation at positions 1 and 2 from the N-terminus, respectively. CD26 is a leukocyte activation marker that possesses dipeptidyl peptidase IV (DPPIV) activity but whose natural substrates and immunological functions had not been previously defined. Several chemokines, including RANTES (regulated on activation, normal T expressed and secreted) are provided, which are substrates for human CD26. The truncated RANTES (3-68) lacked the ability of native RANTES (1-68) to increase the cytosolic calcium concentration in human monocytes, but it still induces this response in macrophages activated with macrophage colony-stimulating factor (M-CSF). RANTES (3-68) retains the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of HIV-1. The invention provides methods for identifying compounds that affect DPPIV-medicated chemokine cleavage, methods for inhibiting HIV infection and treating individuals having or at risk of having HIV infection, methods for diagnosis and/or prognosis of individuals having a chemokine-associated disorder and methods for accelerating wound healing and angiogenesis, all based on the discovery of DPPIV-mediated cleavage of chemokines.
摘要翻译：本发明提供了截短的RANTES（3-68）的核苷酸和氨基酸序列，其具有与野生型RANTES相同的氨基酸序列，但是在N端的位置1和2处具有丝氨酸/脯氨酸截短，分别。 CD26是具有二肽基肽酶IV（DPPIV）活性但其天然底物和免疫功能未被定义的白细胞活化标记。提供了几种趋化因子，包括RANTES（活化调节，正常T表达和分泌），其是人CD26的底物。截短的RANTES（3-68）缺乏天然RANTES（1-68）增加人单核细胞胞质钙浓度的能力，但仍然在巨噬细胞集落刺激因子（M-CSF）激活的巨噬细胞中诱导这种反应。 RANTES（3-68）保留刺激CCR5受体并抑制HIV-1的细胞病变效应的能力。本发明提供了鉴定影响DPPIV-药物趋化因子切割的化合物的方法，用于抑制HIV感染的方法和治疗患有HIV感染或有HIV感染风险的个体的方法，用于具有趋化因子相关病症的个体的诊断和/或预后的方法加速伤口愈合和血管生成，都是基于DPPIV介导的趋化因子切割的发现。

85. 发明申请

US20030186889A1 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction 审中-公开
公开(公告)号：US20030186889A1
公开(公告)日：2003-10-02
申请号：US10239423
申请日：2002-09-23
发明人： Wolf-Georg Forssmann , Ulf Forssmann , Knut Adermann , Aleksandra Heitland , Nicolaj Spodsberg
IPC分类号： G01N033/574 , A61K039/395 , A61K038/10
CPC分类号： C07K14/522 , A61K38/00 , C07K16/2866
摘要： The present invention relates to the provision of a medicament and of a diagnostic agent obtained by proteome analysis, preferably containing at least two different chemokine receptor ligands or chemokine receptor antibodies, and further to the use of at least two different chemokine receptor ligands, chemokine receptor antibodies and/or two different chemokine receptors. As inhibitors, the medicament preferably contains ligands or antibodies of at least two chemokine receptors or the related algorithms of the surface chemokine receptor proteome, and the use of at least one chemokine receptor ligand and/or chemokine receptor, peptides and antibodies and their use for the diagnostics and therapy of tumor diseases and inflammatory diseases. By way of analogy, clusters of analyzed tumor cell surface proteomes, such as ectoproteases, adhesion molecules or various receptor types, can also be used. The invention relates to a method for the purpose of diagnosis and therapy and the medical and industrial use of chemokines and their corresponding receptors, their antagonists including antibodies was found to inhibit cancer growth including metastatic spread, and to suppress inflammatory and auto-immune diseases. The method is based on the finding that chemokines act on specific tumor and inflammation cells via autocrine, paracrine and endocrine routes through the disease-specific constellation of the chemokine receptor proteome. Primary and secondary tumors as well as specific inflammation cells are controlled with respect to their migration and proliferation behavior. By diagnostically detecting the chemokines whose expression and regulation is locally increased and the presence of the chemokine receptor compositions, the possibility arises of critically suppressing or completely preventing cancer growth, metastatic spread of tumors as well as inflammatory and auto-immune diseases.

86. 发明申请

US20030082159A1 Lentiviral vector-mediated gene transfer and uses thereof 有权
标题翻译：慢病毒载体介导的基因转移及其用途
公开(公告)号：US20030082159A1
公开(公告)日：2003-05-01
申请号：US10245050
申请日：2002-09-17
发明人： Binoy Appukuttan , J. Timothy Stout
IPC分类号： A61K048/00
CPC分类号： C12N15/86 , A61K48/00 , A61K48/0075 , C07K14/47 , C07K14/522 , C12N2740/15043 , C12N2740/16043 , C12N2740/16045 , C12N2830/42 , C12N2840/203
摘要： The present invention provides lentiviral vectors that are useful in human gene therapy for inherited or acquired proliferative ocular disease. It furnishes methods to exploit the ability of lentiviral vectors to transduce both mitotically active and inactive cells so that eye diseases may be treated.
摘要翻译：本发明提供可用于人基因治疗遗传或获得性增生性眼部疾病的慢病毒载体。它提供了利用慢病毒载体转导有丝分裂活性和非活性细胞的能力的方法，以便可以治疗眼睛疾病。

87. 发明授权

US06413510B1 Dimeric modified gro&bgr; protein 失效
标题翻译：二聚体改性grobeta蛋白
公开(公告)号：US06413510B1
公开(公告)日：2002-07-02
申请号：US09513153
申请日：2000-02-25
申请人： Peter Lawrence DeMarsh , Kyung Oh Johanson
发明人： Peter Lawrence DeMarsh , Kyung Oh Johanson
IPC分类号： A61K3819
CPC分类号： C07K14/522 , A61K31/424 , A61K31/43 , A61K31/546 , A61K31/7036 , A61K38/00 , C07K14/521 , Y10S514/885 , A61K2300/00
摘要： The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC [SEQ ID NO: 1], gro&agr;[SEQ ID NO:2], gro&bgr;[SEQ ID NO: 3] or gro&ggr;[SEQ ID NO: 4] or multimers thereof, alone or in conjunction with an anti-infective agent. This invention also relates to a new gro&bgr; dimer chemokine.
摘要翻译：本发明涉及使用选自成熟或修饰的KC [SEQ ID NO：1]，groalpha [SEQ ID NO：2]，grobeta [SEQ ID NO：3]或grogamma [SEQ ID NO：1]的趋化因子来预防和治疗败血症的方法：4]或多聚体，单独或与抗感染剂联合使用。本发明还涉及一种新的骨髓二聚体趋化因子。

88. 发明申请

US20020051996A1 MODULAR PROTEIN LIBRARIES AND METHODS OF PREPARATION 失效
标题翻译：模块蛋白图书馆和制备方法
公开(公告)号：US20020051996A1
公开(公告)日：2002-05-02
申请号：US09144838
申请日：1998-08-31
发明人： MICHAEL A. SIANI , JILL WILKEN , REYNA SIMON , STEPHEN B.H. KENT
IPC分类号： C12Q001/00 , G01N033/53 , C07K014/00
CPC分类号： C07K14/523 , A61K38/00 , C07K1/04 , C07K1/047 , C07K14/522
摘要： Novel proteins and libraries comprising them are disclosed. The proteins comprise one or more functional protein modules from different parent protein molecules. The proteins and libraries are exemplified by the preparation of cross-over chemokines comprising various combinations of peptide segments derived from RANTES, SDF-1 and vMIP-I and vMIP-II. The proteins and libraries are extremely pure and can be provided in non-limiting high yields suitable for diagnostic and high-throughput screening assays.
摘要翻译：公开了包含它们的新型蛋白质和文库。蛋白质包含来自不同亲本蛋白质分子的一个或多个功能性蛋白质模块。蛋白质和文库的实例是制备包含衍生自RANTES，SDF-1和vMIP-1和vMIP-II的肽片段的各种组合的交叉趋化因子。蛋白质和文库是非常纯的，可以提供非限制性高产量，适用于诊断和高通量筛选分析。

89. 发明授权

US06110695A Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 失效
标题翻译：调节趋化因子，B淋巴细胞血液吸收剂及其受体BLR1的相互作用
公开(公告)号：US06110695A
公开(公告)日：2000-08-29
申请号：US982493
申请日：1997-12-02
申请人： Michael Dee Gunn , Lewis T. Williams , Jason G. Cyster
发明人： Michael Dee Gunn , Lewis T. Williams , Jason G. Cyster
IPC分类号： A61K38/00 , C07K14/52 , C07K14/715 , C12N15/12 , G01N33/50 , A61K38/19
CPC分类号： C07K14/7158 , C07K14/522 , A61K38/00
摘要： The invention provides methods for identifying agents which modulate the interaction of a chemokine receptor of previously unknown function, Burkitt's Lymphoma Receptor 1 (BLR1), with its ligand, B Lymphocyte Chemoattractant (BLC). The methods find particular application in commercial drug screens.
摘要翻译：本发明提供用于鉴定调节先前未知功能的趋化因子受体伯基特淋巴瘤受体1（BLR1）与其配体B淋巴细胞化学引诱物（BLC）的相互作用的试剂的方法。该方法在商业药物筛选中具体应用。

90. 发明授权

US06107019A Method for preventing HIV-1 infection of CD4.sup.+ cells 失效
公开(公告)号：US06107019A
公开(公告)日：2000-08-22
申请号：US876078
申请日：1997-06-13
申请人： Graham P. Allaway , Virginia M. Litwin , Paul J. Maddon , William C. Olson
发明人： Graham P. Allaway , Virginia M. Litwin , Paul J. Maddon , William C. Olson
IPC分类号： A61K38/00 , C07K14/16 , C07K14/52 , C07K14/715 , C07K14/73 , G01N33/566 , G01N33/569 , G01N33/68 , C12Q1/70
CPC分类号： C07K14/005 , C07K14/522 , C07K14/523 , C07K14/70514 , C07K14/7158 , G01N33/566 , G01N33/56988 , G01N33/6854 , A61K38/00 , C12N2740/16122 , G01N2333/162 , G01N2333/70514 , G01N2333/715 , G01N2500/00 , G01N2500/20
摘要： This invention provides methods for inhibiting fusion of HIV-1 to CD4.sup.+ cells which comprise contacting CD4.sup.+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4.sup.+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4.sup.+ cells which comprise contacting CD4.sup.+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4.sup.+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4.sup.+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4.sup.+ cells effective to prevent fusion of HIV-1 to CD4.sup.+ cells and a pharmaceutically acceptable carrier.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式